ArticleProceedings of the National Academy of Sciences of the United States of America2012
Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
178 citing papers in PubMed, 286 citations in OpenAlex.
- A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.The American journal of clinical nutrition · 2015Trial
- Development landscape of ketohexokinase-C (KHK-C) inhibitors for fructose-driven metabolic disorders: from hit discovery to clinical trials.RSC medicinal chemistry · 2026Review
- Inhibiting fructose metabolism to treat fatty liver.Nature metabolism · 2026Article
- Intestinal fructose catabolism promotes obesity and insulin resistance via ileal lacteal remodeling.Science advances · 2026Article
- Intestinal fructose metabolism drives unsaturated fat absorption and synergizes with GLP-1 receptor agonism to promote weight loss.bioRxiv : the preprint server for biology · 2026Article
- Fructose: metabolic signal and modern hazard.Nature metabolism · 2026Review
- Malvidin-3,5-O-diglucoside derived from spine grape (Vitis davidii) inhibits fructose-induced lipid accumulation in HepG2 cells: beneficial effects on MASLD treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The effect of liver-specific ketohexokinase deletion on the intestinal-liver-kidney axis in high-fructose-induced metabolic syndrome mice.Acta biochimica et biophysica Sinica · 2026Article
- Fructose metabolism as an adaptive survival axis in pancreatic cancer: mechanistic insights and therapeutic implications.Frontiers in medicine · 2026Review
- The association between high fructose corn syrup and the development of type-2 diabetes.Frontiers in clinical diabetes and healthcare · 2026Review
- Fructose uptake by brown adipose tissue is independent of carbohydrate response element-binding protein and does not cause elevatedActa biochimica et biophysica Sinica · 2025Article
- Fructose and insulin: A sweet sabotage hypothesis?Endocrine · 2025Review
- Fructose Malabsorption, Gut Microbiota and Clinical Consequences: A Narrative Review of the Current Evidence.Life (Basel, Switzerland) · 2025Review
- Conformational changes in ketohexokinase are conserved across isozymes and species.Acta crystallographica. Section F, Structural biology communications · 2025Article
- Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer.Pharmacological reviews · 2025Review
- Intestine-derived sorbitol drives steatotic liver disease in the absence of gut bacteria.Science signaling · 2025Article
- Astragaloside IV Alleviates Fructose-Induced Intestinal Metabolic Senescence by Targeting Ketohexokinase Asn261/Ala226 to Preserve Intestinal Stem Cell Homeostasis.ACS central science · 2025Article
- Dietary fibre-adapted gut microbiome clears dietary fructose and reverses hepatic steatosis.Nature metabolism · 2025Article
- LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Circulating glycerate predicts resilience to fructose-induced hepatic steatosis.Cell metabolism · 2025Article
118 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 6 institutions in 5 countries.
Funding
Abstract
Fructose intake from added sugars correlates with the epidemic rise in obesity, metabolic syndrome, and nonalcoholic fatty liver disease. Fructose intake also causes features of metabolic syndrome in laboratory animals and humans. The first enzyme in fructose metabolism is fructokinase, which exists as two isoforms, A and C. Here we show that fructose-induced metabolic syndrome is prevented in mice lacking both isoforms but is exacerbated in mice lacking fructokinase A. Fructokinase C is expressed primarily in liver, intestine, and kidney and has high affinity for fructose, resulting in rapid metabolism and marked ATP depletion. In contrast, fructokinase A is widely distributed, has low affinity for fructose, and has less dramatic effects on ATP levels. By reducing the amount of fructose for metabolism in the liver, fructokinase A protects against fructokinase C-mediated metabolic syndrome. These studies provide insights into the mechanisms by which fructose causes obesity and metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.